Shuttle Pharmaceuticals Holdings, Inc. (SHPH) - Q1 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2025. Shuttle Pharmaceuticals is a discovery and development-stage biopharmaceutical company focused on developing novel cancer immunotherapies and radiation sensitizers, primarily its lead candidate Ropidoxuridine. The company operates as a single segment and is currently in the Phase II clinical trial stage for Ropidoxuridine in brain cancer patients. The filing includes a "Going Concern" warning, stating that existing cash resources and available financing are not expected to fund operations for the next twelve months.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(3,053,007) | $(1,731,031) |
| Net Loss Per Share (Basic & Diluted) | $(0.30) | $(0.83) |
| Cash and Cash Equivalents (End of Period) | $4,512,607 | $1,398,628 |
| Working Capital | $3,177,220 | $677,148 |
| Total Liabilities | $2,024,925 | $1,797,138 |
| Convertible Notes Payable (Fair Value) | $692,128 | $684,205 |
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses increased by 113% to $2.95 million from $1.38 million. This was driven by a 169% increase in R&D expenses ($1.57M vs $0.59M) due to the initiation of Phase II clinical trials and CRO costs, and a 65% increase in legal and professional fees.
- Financing Activity: In March 2025, the company completed an equity offering raising approximately $5.0 million in net proceeds through the issuance of 1.34 million shares and 17.8 million pre-funded warrants. This significantly improved liquidity compared to the prior period.
- Interest Expense: Interest expense decreased by 99% to $6,535 from $497,515 in Q1 2024, primarily due to the settlement of the Alto Convertible Note in late 2024.
- Stock-Based Compensation: Increased to $537,046 from $111,449, largely due to the acceleration of RSU vesting for departing board members following a Revolving Loan Agreement with Bowery Consulting Group.
Outlook, Risks, and Management Commentary
- Going Concern: Management explicitly states that substantial doubt exists regarding the company's ability to continue as a going concern for one year from the filing date without additional equity or debt financing.
- Nasdaq Compliance: The company received notice of non-compliance with the Nasdaq Minimum Bid Price Requirement ($1.00/share). It has until June 30, 2025, to regain compliance or face delisting. The company is seeking shareholder approval for an additional reverse stock split at its May 9, 2025, Annual Meeting.
- Clinical Progress: The Phase II clinical trial for Ropidoxuridine in brain cancer patients commenced in October 2024. The company has expanded its CRO agreement with Theradex Systems, increasing the cost limit to $5.3 million.
- Internal Controls: Management concluded that disclosure controls and procedures were ineffective as of March 31, 2025, citing material weaknesses in accounting transaction processing, segregation of duties, and IT general controls. Remediation efforts are ongoing.
- Subsequent Events: In April 2025, the company paid $2.0 million to an IR Agency for marketing services and issued 4.4 million shares from the exercise of pre-funded warrants.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the $4.5 million cash balance against the $3.2 million in unincurred clinical trial costs and ongoing operating burn rate.
- Nasdaq Delisting Risk: Monitor the stock price relative to the $1.00 threshold and the outcome of the proposed reverse stock split vote on May 9, 2025.
- Internal Control Remediation: Review future filings for evidence of remediation regarding the identified material weaknesses in financial reporting and IT controls.
- Convertible Note Valuation: Assess the impact of the fair value option on convertible notes, which resulted in a $92,479 loss in Q1 2025 due to changes in fair value.
- Legal Contingencies: Monitor the status of the Right of First Refusal (ROFR) dispute with Boustead Securities regarding the recent WestPark Capital engagement.